/
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Orthostatic Intolerance is an emerging landscape with 17 programs across 12 companies.
Intelligence
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Analysis
94%
Small molecule
16 of 17 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 17 classified programs, each share of the total. Modality classified for 100% of 17 pipeline programs.
Analysis
7
clinical trials
Clinical Trials
7 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)